Business Wire

Adva Network Security Layer 2 encryption technology achieves German BSI approval

2.2.2023 11:00:00 EET | Business Wire | Press release

Share

Adva Network Security today announced that its flagship 10Gbit/s edge solution with ConnectGuard Ethernet encryption has been approved for the transmission of classified data by the German Federal Office for Information Security (BSI). With BSI clearance to transport VS-NfD and NATO RESTRICTED (NR) information, the FSP 150-XG118Pro (CSH) enables customers to deploy a secure network access device guaranteed to meet stringent regulatory requirements. With comprehensive demarcation capabilities and an optional server blade, the device offers several additional advantages, such as precise synchronization and NFV hosting. Its approval by the BSI will be a major boost for customers with high security standards.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230201005865/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

BSI approval for Adva Network Security’s 10G Ethernet device will prove key for data protection at the network edge. (Photo: Business Wire)

“We work with public authorities, critical infrastructure operators and enterprises whose networks are particularly threatened by cyberattacks as they often contain the most sensitive and mission-critical data. Today’s announcement will be big news for them. Now it’s possible to securely harness a 10Gbit/s edge solution with a unique set of capabilities such as next-generation timing delivery, network virtualization and comprehensive service assurance,” said Michael Roth, GM of Adva Network Security. “We were the first in the industry to attain BSI clearance for our Layer 1 technology. Now it’s the turn of our Layer 2 solution. As a qualification, BSI approval is one of the most challenging in the industry. Achieving it not only highlights the power of the protection offered by our device, but also our commitment to security in all our business processes.”

The FSP 150-XG118Pro (CSH) is a compact, power-efficient solution for network access that combines 10Gbit/s Carrier Ethernet, IP service demarcation, and aggregation with a rich set of programmability and synchronization features. It offers robust network protection with dynamic key exchange and hardware tamper protection for the most sensitive data, and is also ready to support quantum-safe key exchange. The approval of the FSP 150-XG118Pro (CSH) by the BSI follows certification for the ADVA FSP 3000 Layer 1 encryption solution, which is already playing a key role in the transport of EU- and NATO-classified data. Customers can now have complete peace of mind that their data at both Layers 1 and 2 is secured to the most rigorous standards and compliance requirements.

“Public authorities and critical infrastructure use wide area networks and are looking to apply end-to-end encryption to standard MEF services that meet the strictest industry standards. Now our FSP 150-XG118Pro (CSH) offers a solution that ensures BSI-approved security for metro networks along with the key capabilities needed to deliver tomorrow’s services,” commented Uli Schlegel, senior director of product line management at Adva Network Security. “Our FSP 150-XG118Pro (CSH) meets tight constraints for latency, power and size. It includes a rich set of operational features and supports a pluggable server module for hosting virtualized network functions. With BSI approval, it’s the ultimate choice for rapid innovation and security at the network edge.”

Further information on the FSP 150-XG118Pro (CSH) is available in this video: https://youtu.be/6w7Z3CLBRFE.

About Adva Network Security
Adva Network Security has built a fierce reputation for protecting packet optical networks. We pioneered low-latency, multi-layer encryption solutions that are right now safeguarding data in motion for many mission-critical applications. Our ConnectGuardTM security technology is even combating tomorrow’s quantum security threats. Built by the industry’s leading security experts, our German-based organization helps organizations and government agencies security-harden their networks to ensure critical infrastructure is protected against cyber threats. Our development and manufacturing processes, as well as our security solutions, have been approved and certified by leading governmental security agencies. For more information on how we can help you, please visit www.advasecurity.com.

Published by
Adva Network Security GmbH, Berlin, Germany
www.advasecurity.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For media
Gareth Spence
t +44 1904 699 358
public-relations@adva.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 15:32:00 EEST | Press release

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company's plans to advance the program globally. The FDA granted RPD Designation based on its determination that A-T is a serious and life-threatening disease that primarily affects individ

Esri Introduces ArcGIS Velocity for ArcGIS Enterprise to Power Real-Time GIS Operations13.7.2026 15:00:00 EEST | Press release

Esri, the global leader in location intelligence, has released for general availability ArcGIS Velocity for ArcGIS Enterprise for self-hosted deployments on Windows and Linux. This enables organizations to leverage Velocity from secure on-premises and private cloud environments. Available as software as a service (SaaS) for ArcGIS Online and now for self-hosted environments in ArcGIS Enterprise, Esri’s next-generation geospatial capability delivers real-time analytics on streaming, Internet of Things (IoT), sensor, and asset data. It helps organizations track and visualize public events, supply chains, and infrastructure to identify and respond to potential threats. ArcGIS Velocity for ArcGIS Enterprise expands cloud-native support to enterprise customers across industries in government and business that rely on firewall protection and internal security compliance. ArcGIS Velocity connects to more than 20 ready-to-use feeds for real-time data providers, including Dataminr, Samsara, Fli

HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization of the Edison® Histotripsy Platform13.7.2026 15:00:00 EEST | Press release

HistoSonics, today announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the company’s non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713505048/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image guided platform that is intended for the destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors. It uses the mechanical properties of focused ultrasound, called histotripsy, to liquefy and destroy unwanted tissue and tumors in a single procedure without the need for invasive procedures or radiation, and with potentially fewer side effects than traditional therapies. CE Mark approval follows an increasing number of regulatory clearances and was supported by a growing body of clinical ev

SLB OneSubsea Awarded EPC Contract for Eni’s Baleine Phase 3 Project Offshore Côte d'Ivoire13.7.2026 15:00:00 EEST | Press release

Global energy technology company SLB (NYSE: SLB) announced today that its OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260712734539/en/ SLB OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. Under the contract, SLB OneSubsea will deliver complete subsea production systems (SPS) for 13 wells, reinforcing its role as a core technology and execution partner on one of the most strategically significant offshore developments currently underway in the region. The EPC scope includes subsea trees, umbilical, manifolds, multiphase flowmeters and control systems, along with installation, commissionin

Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer13.7.2026 13:00:00 EEST | Press release

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that it has entered into a securities purchase agreement for a private placement of approximately $85 million in upfront gross proceeds, before the deduction of private placement expenses, and up to an additional $255 million upon the full exercise of purchase warrants. The financing was led by Commodore Capital, with participation from RA Capital Management, TCGX, Invus, and Ligand Pharmaceuticals. The net proceeds of this financing are expected to support Agenus’ strategic prioritization of botensilimab and balstilimab (BOT+BAL) for the neoadjuvant treatment of microsatellite-stable (MSS) colon cancer, including advancement of ROBBIN1, the Company’s planned registrational Phase 3 neoadjuvant trial in microsatellite-stable (MSS) colon cancer. High-risk Stage II and Stage III MSS colon cancer affect an estimated 38,000 patients annually in the US and more than 200,000 patients worldwide,2 representing a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye